Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature

Singh, Ajeet; Bharadwaj, Sujana J; C, Anju George; Ganguly, Satyaki

doi:10.1111/jocd.14945

Cited by 12 publications

(8 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These clinical trials provide evidence of the efficacy of COVID-19 vaccines in preventing symptomatic SARS-CoV-2 infection, whereas pemphigus is a rare occurrence in the general population. The vaccines are well tolerated, with mild and easily manageable adverse events in most cases [ 28 ]. Based on preliminary studies, pemphigus is not a contraindication to vaccination; and the overall benefit of avoiding severe COVID-19 through vaccination will outweigh the potential risks of disease flare [ 29 ].…”

Section: Covid-19 Vaccine: Trigger or Exacerbate Pemphigus?mentioning

confidence: 99%

Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies

Huang

Liang

Zhang

et al. 2022

JCM

View full text Add to dashboard Cite

Pemphigus is a rare autoimmune blistering disease, involving potentially life-threatening conditions often requiring immunosuppression. Currently, the COVID-19 pandemic caused by severe acute respiratory disease coronavirus 2 (SARS-CoV-2) infection has become a global public emergency. Vaccines are the most effective defense against COVID-19 infection. However, in clinic, there are cases of new onset or flare of pemphigus following COVID-19 vaccination, where vaccines have manifested significantly desirable risk-benefit profiles for patients. Although Rituximab, as first-line therapy, may impair humoral immunity, pemphigus may not predispose to develop COVID-19 infection compared to a healthy population. Conversely, delay or interruption of immunosuppressants probably results in unfavorable clinical outcomes for disease progression. Overall, clinicians should encourage their patients to undergo the vaccination after a comprehensive assessment. The definite association between COVID-19 vaccination and pemphigus remains to be further elucidated. Herein, we provide an overview of the published studies to date on COVID-19 and pemphigus as well as the exploration of their complicated interplay. In addition, we discuss the management strategies for pemphigus patients in this special period, in an effort to more effectively establish a standard treatment paradigm for this particular patient group.

show abstract

Section: Covid-19 Vaccine: Trigger or Exacerbate Pemphigus?mentioning

confidence: 99%

Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies

Huang

Liang

Zhang

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…[109][110][111][112][113][114][115][116][117][118][119] The largest study on 77 patients developing alopecia areata (39) or a worsening of the disease (38) has been reported by Nguyen et al Unfortunately, it is not possible to correlate alopecia areata development and the type of vaccine. 120 Regarding bullous disorders, a total of 26 cased of pemphigus vulgaris have been reported following COVID-19 vaccination, [121][122][123][124][125][126][127][128][129][130][131][132][133][134][135] with several implications in treatment and management. 136 Moreover, 40 cases of pemphigoids have been described.…”

Section: Resultsmentioning

confidence: 99%

“… BNT162b2: 71 mRNA-1273: 12 AZD1222: 15 Ad26.COV2: 0 Alopecia areata 24 Scollan et al 109 (9), Babadjouni et al 110 (3), Rossi et al 111 (3), Chen et al 112 (2), Abdalla et al 113 (1), Gamonal et al 114 (1), Ho et al 115 (1), Su et al 116 (1), Gallo et al 117 (1), May Lee et al 118 (1), Essam et al 119 (1). BNT162b2: 14 mRNA-1273: 4 AZD1222: 6 Ad26.COV2: 0 Pemphigus vulgaris 26 Martora et al 121 (7), Zou et al 122 (3), Gui et al 123 (2), Rouatbi et al 124 (2), Aryanian et al 125 (1), Koutlas et al 126 (1), Knechtl et al 127 (1), Ong et al 128 (1), Yıldırıcı et al 129 (1), Singh et al 130 (1), Norimatsu et al 131 (1), Agharbi et al 132 (1), Almasi-Nasrabadi et al 133 (1), Corrá et al 134 (1), Solimani et al 135 (1). BNT162b2: 15 mRNA-1273: 6 AZD1222: 5 Ad26.COV2: 0 Pemphigoids 40 Maronese et al 137 (21), Maronese et al 138 (3), Hali et al 139 (3), Gambichler et al 140 (2), Shanshal et al 141 (1), Desai et al 142 (1), Fu et al 143 (1), Alshammari et al 144 (1), Hung et al 145 (1), Pauluzzi et al 146 (1), Dell’Antonia...…”

Section: Methodsmentioning

confidence: 99%

“…Merhy et al62 (1), Camela et al63 (1), Kato et al69 (1), Diab et al70 (1), Zagaria et al71 (1), Awada et al72 (1), Picone et al73 (1), Hlaca et al74 (1), Zengarini et al75 (1), Masseran et al76 (1), Gamonal et al64 (1), Alrawashdeh et al65 (1), Shakoei et al66 (1). Zou et al122 (3), Gui et al123 (2), Rouatbi et al124 (2), Aryanian et al125 (1), Koutlas et al126 (1), Knechtl et al127 (1), Ong et al128 (1), Yıldırıcı et al129 (1), Singh et al130 (1), Norimatsu et al131 (1), Agharbi et al132 (1), Almasi-Nasrabadi et al133 (1),…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

“…La mayor cantidad de casos fueron de novo, como en este paciente, y en un menor porcentaje fueron exacerbación de la enfermedad de base 7 . Las diferentes características de los casos publicados en la literatura se resumen en la tabla 1 1,[4][5][6][7][8][9][10][11][12][13] .…”

Section: Discussionunclassified

Reporte de un caso de pénfigo vulgar gatillado por vacunación contra la COV ID-19 y revisión de la literatura

Ginzburg¹,

Forero²,

Candiz³

et al. 2023

MCUT

View full text Add to dashboard Cite

Pemphigus vulgaris is an autoimmune mucocutaneous blistering disease that may be trigger by different factors, such as drugs or vaccines. There are few cases recently published on the association between pemphigus vulgaris and vaccination against COVID-19. We report a case of pemphigus vulgaris probably triggered by vaccination against COVID-19 and a review of the cases reported in medical publications with this relationship is perform.

show abstract

Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature

Cited by 12 publications

References 24 publications

Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies

Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Reporte de un caso de pénfigo vulgar gatillado por vacunación contra la COV ID-19 y revisión de la literatura

Contact Info

Product

Resources

About